| Garlanda Cecilia |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Greco Luana |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Jaillon Sebastien |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mantovani Alberto |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mapelli Sarah |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Marchesi Federica |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Pasqualini Fabio |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Abdurahim Saeed |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Alberici Federico |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Anstadt Robert |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Antonucci Luca |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Ariceta Gema |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Armelloni Silvia |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Armstrong Lye |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Assanelli Andrea |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Atanasiu Doina |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Banda Nirmal |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Barbarossa Annalisa |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Barr William |
Sex Chromosome Regulation of Complement System Activity: Evidence for Post-Transcriptional Control of C3 and C4 Levels
|
| Bassanese Giulia |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Battaglino Cedric |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Beeckmans Hanne |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Benigni Ariela |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Berthenet Kevin |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Blagojevic Aleksandra |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Blom Anna |
Complement factor H is a novel ligand for the inducible T cell co-stimulator (ICOS) and promotes survival or regulatory T cells in the glioma microenvironment
|
| Bodnaruk Iryna |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Bomback Andrew |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Bongoni Anjan |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Bos Saskia |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Bosàkovà Veronika |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Boudhabhay Idris |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
Cell-intrinsic complement in endothelium
|
| Bouyain Samuel |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Bracke Laura |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Brekke Ole- |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Brenner Michael |
Granzyme K Activates the Entire Complement Cascade
Granzyme K-driven complement activation
|
| Bresin Elena |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Bright Matthew |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
|
| Butler Samuel |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Cairns Tina |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Cappoli Andrea |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Carriero Roberta |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Castellano Giuseppe |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Catalano Marco |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Cedzyński Maciej |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Celik Selvi |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Cerniauskas Edvinas |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Ceulemans Laurens |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Chang Nan-Shan |
Serum complement internalization is needed for UV-mediated nuclear bubbling cell death
|
| Chen Xi |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Ciceri Fabio |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Cicia Donatella |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Claes Sandra Claes |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Cohen Gary |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Colombo Federico |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Connolly E. Sander |
Complement Activity in Emboli Retrieved During Thrombectomy for Ischemic Stroke
|
| Cowan Peter |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Curtin Karen |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Czerwiński Marcin |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Czyszczoń Paula |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Dabrowska-Schlepp Paulina |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Dambra Monica |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| De Castro Deus Marina |
Cell-intrinsic complement in endothelium
|
| De winter Karen |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Delahaye Tim |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Delmas Yahsou |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Deschatelets Pascal |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Dettner Alina |
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
The involvement of complement system in immune mediated platelet clearance processes
|
| Developement team ARDA |
The story of empasiprubart (ARGX-117), a long acting inhibitory C2 antibody, from bench to MMN patients
|
| Dixon Bradley |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Doherty Mary |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Donadelli Roberta |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Donado Carlos |
Granzyme K Activates the Entire Complement Cascade
|
| Duan Huiquan |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Eikrem David |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
|
| Eitel Ingo |
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
|
| Emblem Åse |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Emma Francesco |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Fakhouri Fadi |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Filip-Psurska Beata |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Fisicaro Nella |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Fleckenstein Monika |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Fontana Juan |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Friščić Jasna |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Fromell Karin |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
|
| Fung Jenny |
Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Gaboriaud Christine |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Gadzinowski Mariusz |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Gajek Gabriela |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Gál Péter |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Gale Daniel |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Garcia Brandon |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Gargiulo Antonio |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Garlanda Cecilia |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
Humoral Innate Immunity and Acute Phase Proteins in COVID-19
|
| Geisbrecht Brian |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Geisler Sven |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Ghaboosh Hiba |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Ghebrehiwet Berhane |
The C1q and gC1qR proteins as therapeutic targets in cancer
|
| Giannini Carolina |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Goicoechea de Jorge Elena |
Complement dysregulation behind the scenes in ANCA-associated vasculitis
|
| Gragoll Carolin |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Greenbaum Larry |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Grizzi Fabio |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Grønli Renathe |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Gudino Victoria |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Gumas Justin |
Immunostimulatory tRNA-derived RNAs in the circulation of patients with tuberculosis infection
|
| Guse Kirsten |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Guzzo Isabella |
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Hack Erik |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Hageman Jill |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Hajishengallis George |
Maladaptive trained immunity and chronic inflammation
|
| Hallam Dean |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Han Seung Hyeok |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Hanack Christina |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Harris Claire |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Harvey Friedman |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Haut Nolwenn |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Höchsmann Britta |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Hoffmann Markus |
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Holers V |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Hook Lauren |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Hoxha Elion |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Huber-Lang Markus |
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
The involvement of complement system in immune mediated platelet clearance processes
|
| Ikehata Masami |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Imanifard Zahra |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Isbel Nicole |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Iuzzolino Lucia |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Jarych Dariusz |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Jin Xin |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Joakimsen Ingrid |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Jonsson A. Helena |
Granzyme K Activates the Entire Complement Cascade
|
| Julianisya Alana |
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Kaes Janne |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Karlsen Bård |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Kasperkiewicz Katarzyna |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Kavanagh David |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Kawamura Takuya |
Immunostimulatory tRNA-derived RNAs in the circulation of patients with tuberculosis infection
|
| Ke BoJun |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| King Ben |
Complement and Diabetes in rodent models: complement controls metabolism, and metabolism controls complement
|
| Kirino Yohei |
Immunostimulatory tRNA-derived RNAs in the circulation of patients with tuberculosis infection
|
| Kiss Bence |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Klint Cecilia |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Kocsis Andrea |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Koehl Joerg |
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
|
| Köhl Jörg |
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
|
| Kolev Martin |
A novel multiplex functional assay can be utilized to elucidate the mechanisms of the complement system.
|
| Kor Viktor |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Kortleven Pheline |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Kozma Viktoria |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Kulak Klaudia |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Kurzawa Marzena |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Lako Majlinda |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Lambris John |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
Therapeutic complement modulation at the forefront of novel immunotherapies: Misconceptions, myths, and novel insights
The involvement of complement system in immune mediated platelet clearance processes
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Lee John |
Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Li Min |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Licht Christoph |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Lill Markus |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Link-Lenczowski Paweł |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Liu Jin |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| López Lázaro Luis |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Łukasiewicz Jolanta |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Maciejewska Anna |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Magrini Elena |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Makhkamova Munisakhon |
Asymmetric dimethylarginine: a biomarker bridging coronary heart disease and metabolical associated steatotic liver disease
|
| Malik Kamil |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Mannes Marco |
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
The involvement of complement system in immune mediated platelet clearance processes
|
| Marasà Maddalena |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Maritati Federica |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Martynowski Dariusz |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Mastaglio Sara |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Mastellos Dimitris |
TBA - Mastellos
Compstatins abolish pathogenic fibroblast function associated with inflammatory maladaptation of tissues
|
| Mastrangelo Antonio |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Matteoli Gianluca |
Targeting Fibroblast-Derived C3: A Potential Therapeutic Strategy to Halt Chronic Inflammation in IBD.
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Mattinzoli Deborah |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| McRae Jennifer |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Meyer Florian |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Mikołajczyk Krzysztof |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Mizuno Masashi |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Mohler Jennifer |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Mollnes Tom |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Montagner Sara |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Morgan B. Paul |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
Targeting complement in brain diseases.
|
| Moro Marc |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Muntz Fenella |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Nagy Zoltán |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Németh Bálint |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Nester Carla |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Neves de Holanda Maria Izabel |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Nguyen Van Dien |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
|
| Nilsson Bo |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Nilsson Ekdahl Kristina |
Activation of native C3 without proteolytic cleavage induced by phosphatidyl serine containing membranes.
|
| Noris Marina |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Novysedlak Rene |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Olcina Monica |
Selective pressures driving altered complement protein expression in the tumour microenvironment
|
| Padoa Sofia |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Pál Gábor |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Pappas Chris |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Penati Francesca |
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Pettersen Kristin |
Combined complement C3 and CD14 inhibition reduce live Escherichia coli-induced inflammation, but not platelet activation in the presence and absence of antibiotics
|
| Pezone Giovanni |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Pickering Matthew |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Pinheiro Sofia |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Pio Ruben |
Targeting complement in immunosuppressive tumor microenvironments
|
| Piras Rossella |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
|
| Podestà Manuel |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Poppelaars Felix |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Pouw Richard |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Quintana Porras Luis Fernando |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Rabbani Said |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
|
| Ranson Neil |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Ratajczak Mariusz |
The different responsiveness of C3- and C5-deficient murine BM cells to oxidative stress explains why C3 deficiency, in contrast to C5 deficiency, correlates with better pharmacological mobilization and engraftment of hematopoietic stem cells.
|
| Rawish Elias |
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
|
| Read Austin |
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Redissi Alaeddine |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
|
| Remuzzi Giuseppe |
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
In vitro efficacy of recombinant Factor H, CPV-104, to antagonize alternative pathway C3/C5 convertases stabilization by NeFs from patients with primary C3 glomerulopathy (C3G)
|
| Rezola Artero Mikel |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
|
| Richards Burt |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Ricklin Daniel |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
|
| Risitano Antonio Maria |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Rodo Jordi |
A Novel Tool for Complement Activation Profiling in AAV Gene Therapy
|
| Rojas Rechy Moises |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Rossi Véronique |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Roumenina Lubka |
Integrated complementomics reveals myeloid-mediated pro-tumoral reprogramming of ccRCC cells through intracellular C3
Complement in Sickle Cell Disease
Cell-intrinsic complement in endothelium
|
| Ruggeri Annalisa |
Complement therapeutics in acute respiratory distress syndrome (ARDS) beyond SARS-CoV-2: a clinical perspective
|
| Rusack Timo |
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
|
| Rüthemann Peter |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Sahu Arvind |
Viral teachings on complement regulation
|
| Salas Azucena |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Salvaris Evelyn |
Targeting the complement lectin pathway with a highly specific MASP-2 inhibitor protects against renal ischemia-reperfusion injury
|
| Santhosh Sneha |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Savukoski Susa |
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
The involvement of complement system in immune mediated platelet clearance processes
|
| Saw Wan Ting |
Unveiling the unique interaction mechanism of herpes simplex virus 2 glycoprotein C with C3b
|
| Schaefer Franz |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Schmidt Christoph |
Complement activation in the intensive care unit: Therapeutic approaches on the central hub?
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Schmitz-Valckenberg Steffen |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Schneider Michael |
Astrocyte-Derived Complement C3 Drives Metabolic Syndrome via C3a Receptor Activation in Hypothalamic Appetite-Regulating Neurons
Therapeutic Potential of the C3aR Antagonist JR14a in Heart Failure With Preserved Ejection Fraction (HFpEF)
|
| Schols Dominique |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Schrezenmeier Hubert |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Schubart Anna |
Iptacopan (Fabhalta) for the treatment of complement-mediated diseases
In vitro effect of FB inhibitor in patients with primary Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).
|
| Schwaeble Wilhelm |
Augmenting cytotoxicity of pathogen-specific antibodies that initiate complement activation independent of the classical pathway
|
| Schwardt Oliver |
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
|
| Seager Nathan |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Shigematsu Megumi |
Immunostimulatory tRNA-derived RNAs in the circulation of patients with tuberculosis infection
|
| Sichau Jannik |
Breakthrough haemolysis in PNH patients on C3 inhibition: a role for immune adherence
|
| Simberg Dmitri |
Complement Alternative Pathway Inhibitors for Hemocompatibility of Nanoparticles in Multiple Animal Species.
|
| Skurnik Mikael |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
|
| Smiesko Martin |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
Design and Evaluation of Glycomimetics as Ficolin-1 Antagonists
|
| Sobała Łukasz |
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Spirig Rolf |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Steel David |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Stravalaci Matteo |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Subramaniam and collaborators Shankar |
A spatial and tissue digital landscape of triple negative breast cancer and complement pathways
|
| Świerzko Anna |
Dissecting the role of bacterial outer membrane vesicle- (OMV)-dependent complement activation in systemic inflammatory response syndrome (SIRS)
Influence of N-glycosylation of the SARS-CoV-2 Spike protein on its interaction with collectins and complement activation
|
| Szamosi Johan |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Tenner Andrea |
Knowing the Enemy: Selectively targeting complement to treat Alzheimer disease and related dementias
|
| Theisen Erin |
Granzyme K Activates the Entire Complement Cascade
|
| Thielens Nicole |
Complement C1 proteases as possible new therapeutic targets in diseases
|
| Thomas Julie |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Thurman Joshua |
RNA profiling, protein expression and gene deletion studies in rheumatoid arthritis patient synovium and murine models identifies critical roles for activation pathway effector mechanisms as well as factor H (FH) and FH-related families in disease pathogenesis
|
| Toso Marc |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Traggiai Elisabetta |
Contribution of complement activating anti-PLA2R1 autoantibodies in membranous nephropathy
|
| Trombetta Elena |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Tsai Cheng-Chang |
Serum complement internalization is needed for UV-mediated nuclear bubbling cell death
|
| Van De Kar Nicole |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| van de Logt Anne-Els |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
|
| Van de Sompel Ariella |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Van de Walle Inge |
The story of empasiprubart (ARGX-117), a long acting inhibitory C2 antibody, from bench to MMN patients
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Van Slambrouck Jan |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Vanaudenaerde Bart |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Vermeire Severine |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Verstockt Bram |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Veuskens Bert |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
| Viatore Marika |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Vivarelli Marina |
Real-world evidence for efficacy and safety of Iptacopan and Pegcetacoplan in patients with primary membranoproliferative glomerulonephritis (MPGN)
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
A case of a young C3G patient with a multifactorial genetic background, treated with pegcetacoplan
|
| Vos Robin |
Unraveling the contribution of complement in the initial days post lung transplantation
|
| Walker Patrick |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Wallace Dean |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Wang Zhongshen |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Whitfield Phil |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Widmer Kevin |
Keeping host defense on a leech: Gigastasin as a versatile template for designing complement and coagulation system modulators
|
| Williams Brandi |
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
|
| Woodruff Trent |
Targeting C5a Inflammation in ALS: Ex Vivo Findings from PMX205 Phase Ib Trial
A pathogenic role of C5aR2 activation in Amyotrophic Lateral Sclerosis.
|
| Wu Wei |
Inhibiting the Complement Classical Pathway by Blocking Activation of the C1r Zymogen
|
| Xiao Junyu |
Structural insights into IgM and complement activation
|
| Xie Long |
Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of AMD by restoring lysosomal function
|
| Zanella Gaia |
Activated fibroblasts produce high level of complement component 3 during intestinal inflammation
|
| Zanoni Francesca |
Cell-intrinsic complement system activation mediates reprogramming of human Podocytes: role of SGLT2 inhibitors
|
| Zecher Daniel |
VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN
|
| Zelek Wioleta |
Mapping complement expression in the brain: implications for neurodegenerative disease therapeutics.
Targeting complement in brain diseases.
|
| Zouace Moussa |
Refinement of associations between age-related macular degeneration and regulators of complement activation for discovery and improved translation
|
| Zouache Moussa |
Age-related macular degeneration: a tale of two RPE/choroid-centric diseases, of which only one is complement-driven
Chromosome 1q32 Haplotypes Define a Fundamental Complement Factor H Protein Family Complotype That Modulates Susceptibility to Age-related Macular Degeneration in Individuals of European Ancestry
|
